FMP
Geron Corporation
GERN
NASDAQ
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
3.3 USD
-0.04 (-1.21%)
About
ceo
Dr. John A. Scarlett M.D.
sector
Healthcare
industry
Biotechnology
website
https://www.geron.comexchange
NASDAQ
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
CIK
0000886744
ISIN
US3741631036
CUSIP
374163103
Address
919 East Hillsdale Boulevard
Phone
650 473 7700
Country
US
Employee
141
IPO Date
Jul 31, 1996
Key Executives
